[HTML][HTML] Integration of artificial intelligence in lung cancer: Rise of the machine

C Ladbury, A Amini, A Govindarajan… - Cell Reports …, 2023 - cell.com
The goal of oncology is to provide the longest possible survival outcomes with the
therapeutics that are currently available without sacrificing patients' quality of life. In lung …

[HTML][HTML] Artificial intelligence and lung cancer: impact on improving patient outcomes

Z Gandhi, P Gurram, B Amgai, SP Lekkala… - Cancers, 2023 - mdpi.com
Simple Summary In this comprehensive review, we aimed to summarize the advances made
by artificial intelligence in the field of lung cancer screening, diagnosis, and management …

[HTML][HTML] Clinical network systems biology: traversing the cancer multiverse

I Mambetsariev, J Fricke, SB Gruber, T Tan… - Journal of Clinical …, 2023 - mdpi.com
In recent decades, cancer biology and medicine have ushered in a new age of precision
medicine through high-throughput approaches that led to the development of novel targeted …

[HTML][HTML] Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine …

MR Sayer, I Mambetsariev, KH Lu, CW Wong… - Frontiers in …, 2023 - frontiersin.org
Introduction Immune checkpoint inhibitors (ICIs) produce a broad spectrum of immune-
related adverse events (irAEs) affecting various organ systems. While ICIs are established …

[HTML][HTML] Selpercatinib and pralsetinib induced chylous ascites in RET-rearranged lung adenocarcinoma: a case series

J Fricke, J Wang, N Gallego, I Mambetsariev, P Kim… - Clinical Lung Cancer, 2023 - Elsevier
Clinical Practice Points• The selective RET-TKIs, ie, selpercatinib and pralsetinib are
effective against RET fusions in patients with NSCLC.• Chylous ascites (CA) is an extremely …

[HTML][HTML] Characterization of KRAS Mutational Regression in Oligometastatic Patients

A Ottaiano, RP de Vera d'Aragona, AM Trotta… - Frontiers in …, 2022 - frontiersin.org
Background We previously reported rare regressive genetic trajectories of KRAS pathogenic
mutations as a specific hallmark of the genuine oligometastatic status in colorectal cancer …

[HTML][HTML] Clinical and Immunologic Characteristics of Non-Hematologic Cancers in Patients with Inborn Errors of Immunity

S Delavari, Y Wang, T Moeini shad, S Pashangzadeh… - Cancers, 2023 - mdpi.com
Simple Summary Comprehensive studies on non-hematologic tumors in patients with inborn
errors of immunity are scarce. Using a well-established registry of patients with long-term …

[HTML][HTML] Genetic alterations of KRAS and TP53 in intrahepatic cholangiocarcinoma associated with poor prognosis

J Peng, S Fang, M Li, Y Liu, X Liang, Z Li… - Open Life …, 2023 - degruyter.com
The aim of this study is to investigate certain genetic features of intrahepatic
cholangiocarcinoma (ICCA). A total of 12 eligible ICCA patients were enrolled, and tumor …

Implications of Evolutionary Dynamics for Cancer Treatment and Prevention

RC Jackson - Evolutionary Dynamics of Malignancy: The Genetic and …, 2023 - Springer
Understanding the evolutionary dynamics of malignancy has implications for prevention,
diagnosis, and treatment of cancer. Cancer incidence can be partially prevented by …